What is the recommended initial treatment and monitoring plan for autoimmune hepatitis?

Recommended Initial Treatment for Autoimmune Hepatitis

Start with predniso(lo)ne at 0.5 mg/kg/day (up to 1 mg/kg/day in severe/advanced disease) combined with azathioprine 50 mg/day initially, increasing to 1-2 mg/kg/day, or alternatively mycophenolate mofetil 1.5-2 g/day. 1, 2

First-Line Treatment Regimen

Corticosteroid Component

• Prednisolone dosing: Start at 0.5 mg/kg/day (maximum 40 mg/day in adults, up to 2 mg/kg in children with 40 mg maximum) 2
• Higher doses (up to 1 mg/kg/day) should be reserved for severe or advanced disease, as they achieve higher biochemical response rates but at the cost of significantly more adverse events 1
• Budesonide 9 mg/day is an alternative in non-cirrhotic adults if major cosmetic concerns exist, though not routinely recommended over prednisolone 2
• Critical caveat: Never use budesonide in cirrhotic patients due to first-pass metabolism concerns 2

Steroid-Sparing Agent

The combination approach reduces corticosteroid-related side effects compared to monotherapy:

Azathioprine protocol 1, 2:

• Start at 50 mg/day initially (1 mg/kg/day in adults, 2-2.5 mg/kg in children)
• Wait 2 weeks after starting corticosteroids before adding azathioprine if bilirubin <6 mg/dl (to avoid diagnostic confusion between non-response and azathioprine toxicity)
• Gradually increase to final dose of 1-2 mg/kg/day by week 4
• Check TPMT enzyme activity before starting if readily available to exclude homozygous deficiency 2

Mycophenolate mofetil alternative 1:

• Start at 1,000 mg/day, increase to 1,500-2,000 mg/day by week 2
• Can be initiated simultaneously with corticosteroids (no delay needed)
• Mandatory contraception counseling: MMF is teratogenic; both male and female patients require two methods of birth control during treatment and up to 12 weeks after withdrawal 1

Special Circumstances for Monotherapy

Use prednisolone alone (0.5 mg/kg/day, maximum 40 mg/day) in 2:

• Decompensated cirrhosis
• Current or recent malignancy
• Uncertain AIH diagnosis
• Suspected precipitant with expectation of short treatment duration

Monitoring Plan

Initial Phase (First 6 Months)

Laboratory monitoring frequency 1:

• Weeks 4,12, and 24: ALT and IgG (efficacy parameters)
• First month: Weekly to biweekly monitoring, particularly for azathioprine-treated patients (toxicity most common in first 6 weeks) 1
• MMF patients: Can monitor at 4 weeks (MMF toxicity is rare) 1

Safety biomarkers to monitor 2:

• Complete blood count (watch for bone marrow suppression with azathioprine)
• Liver function tests
• Thyroid function every 6-12 months (thyroid disorders can develop during follow-up) 1

Maintenance Phase (After 6 Months)

If complete biochemical response (CBR) achieved 1, 2:

• Monitor every 3-6 months to confirm sustained CBR
• CBR defined as normalization of ALT and IgG levels

Corticosteroid tapering strategy 1, 2:

• Taper should be individualized according to biochemical response
• Rapid tapering (5-10 mg every 1-2 weeks) is desirable but must follow response
• Reduce gradually over 1-3 months to 5-10 mg/day (budesonide to 6 mg/day)
• As steroids decrease, azathioprine can increase from 1 to 2 mg/kg/day with appropriate blood count monitoring 2

Non-Invasive Fibrosis Assessment

• Transient elastography should be performed regularly to monitor liver fibrosis 1
• Consider assessment at 2-3 year intervals 2

Proactive Management of Treatment-Related Complications

Bone Health 1, 2

• DEXA scan: Baseline and periodic follow-up (high incidence of osteoporotic fractures: 17.5 per 1,000 person-years) 1
• FRAX score calculation in adults starting steroids; high-risk patients may need bisphosphonates before DEXA results 2
• Vitamin D supplementation and adequate calcium intake for all patients on long-term corticosteroids 1, 2

Ophthalmologic Monitoring 1

• Baseline intraocular pressure measurement
• Periodic ophthalmic check-ups during corticosteroid therapy (two-thirds of patients develop raised intraocular pressure, mostly asymptomatic)

Infection Screening 2

• HBV screening: Prophylactic nucleotide therapy if HBsAg positive or HBV core antibody positive with rituximab
• Monitor for HBV reactivation if core antibody positive on other treatments

Common Pitfalls to Avoid

1. Starting azathioprine too early: Wait until bilirubin <6 mg/dl and ideally 2 weeks after corticosteroids to distinguish non-response from azathioprine toxicity 1

2. Using budesonide in cirrhosis: This is contraindicated due to impaired first-pass metabolism 2

3. Inadequate contraception counseling with MMF: Both male and female patients require strict birth control measures 1

4. Overly aggressive initial corticosteroid dosing: Higher doses (>0.5 mg/kg/day) increase adverse events without proportional benefit except in severe/advanced disease 1, 3

5. Premature dose reduction: Tapering must be guided by biochemical response, not arbitrary timelines 1

6. Missing TPMT testing: Homozygous TPMT deficiency requires substitution with MMF rather than azathioprine 2

The evidence strongly supports combination therapy over monotherapy, with recent meta-analysis showing lower mortality with prednisolone plus azathioprine versus prednisolone alone (RR 0.38) 3. Treatment should achieve clinical and biochemical response while minimizing corticosteroid exposure through individualized tapering based on response status.